97 related articles for article (PubMed ID: 24337478)
1. Comment on "Progesterone/RANKL is a major regulatory axis in the human breast".
Wang J; Gupta A; Hu H; Chatterton RT; Clevenger CV; Khan SA
Sci Transl Med; 2013 Dec; 5(215):215le4. PubMed ID: 24337478
[TBL] [Abstract][Full Text] [Related]
2. Progesterone/RANKL is a major regulatory axis in the human breast.
Tanos T; Sflomos G; Echeverria PC; Ayyanan A; Gutierrez M; Delaloye JF; Raffoul W; Fiche M; Dougall W; Schneider P; Yalcin-Ozuysal O; Brisken C
Sci Transl Med; 2013 Apr; 5(182):182ra55. PubMed ID: 23616122
[TBL] [Abstract][Full Text] [Related]
3. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase.
Hu H; Wang J; Gupta A; Shidfar A; Branstetter D; Lee O; Ivancic D; Sullivan M; Chatterton RT; Dougall WC; Khan SA
Breast Cancer Res Treat; 2014 Aug; 146(3):515-23. PubMed ID: 25007964
[TBL] [Abstract][Full Text] [Related]
4. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
5. Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.
Haynes BP; Viale G; Galimberti V; Rotmensz N; Gibelli B; Smith IE; Dowsett M
Breast Cancer Res Treat; 2014 Nov; 148(2):327-35. PubMed ID: 25367875
[TBL] [Abstract][Full Text] [Related]
6. Progestogens and risk of breast cancer: a link between bone and breast?
González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
[TBL] [Abstract][Full Text] [Related]
7. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
8. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis.
Zoi I; Karamouzis MV; Adamopoulos C; Papavassiliou AG
Trends Mol Med; 2016 Oct; 22(10):839-850. PubMed ID: 27567286
[TBL] [Abstract][Full Text] [Related]
9. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
10. RANK expression as a prognostic and predictive marker in breast cancer.
Pfitzner BM; Branstetter D; Loibl S; Denkert C; Lederer B; Schmitt WD; Dombrowski F; Werner M; Rüdiger T; Dougall WC; von Minckwitz G
Breast Cancer Res Treat; 2014 Jun; 145(2):307-15. PubMed ID: 24737168
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-sensitive progesterone production by rhesus monkey luteal cells in vitro: a function of age of the corpus luteum during the menstrual cycle.
Stouffer RL; Nixon WE; Gulyas BJ; Hodgen GD
Endocrinology; 1977 Feb; 100(2):506-12. PubMed ID: 401732
[TBL] [Abstract][Full Text] [Related]
12. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
13. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
[TBL] [Abstract][Full Text] [Related]
14. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
15. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
16. The RANKL-RANK Story.
Nagy V; Penninger JM
Gerontology; 2015; 61(6):534-42. PubMed ID: 25720990
[TBL] [Abstract][Full Text] [Related]
17. Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle.
Chaireti R; Gustafsson KM; Byström B; Bremme K; Lindahl TL
Hum Reprod; 2013 Jul; 28(7):1846-52. PubMed ID: 23592222
[TBL] [Abstract][Full Text] [Related]
18. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse.
Fernandez-Valdivia R; Mukherjee A; Ying Y; Li J; Paquet M; DeMayo FJ; Lydon JP
Dev Biol; 2009 Apr; 328(1):127-39. PubMed ID: 19298785
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
20. Human fallopian tube epithelium co-culture with murine ovarian follicles reveals crosstalk in the reproductive cycle.
Zhu J; Xu Y; Rashedi AS; Pavone ME; Kim JJ; Woodruff TK; Burdette JE
Mol Hum Reprod; 2016 Nov; 22(11):756-767. PubMed ID: 27542947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
